VITAL Act of 2025

119 HR 3631 IH: Vaccines in Trial and Liability Act of 2025 U.S. House of Representatives 2025-05-29 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 3631 IN THE HOUSE OF REPRESENTATIVES May 29, 2025 Mr. Green of Tennessee introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To criminalize fraudulent statements made with respect to clinical vaccine trials. 1. Short title This Act may be cited as the Vaccines in Trial and Liability Act of 2025 or the VITAL Act of 2025 . 2. Medical research company or sponsor (a) In general Chapter 47 of title 18, United States Code, is amended by adding at the end the following: 1041. Clinical vaccine trial fraud Whoever, being a medical research company or sponsor, makes a fraudulent statement to, or conceals from, any department or agency of the United States, any material data collected from a clinical vaccine trial, shall be fined under this title, imprisoned not more than 5 years, or both. . (b) Clerical amendment The table of sections for chapter 47 of title 18, United States Code, is amended by adding at the end the following: 1041. Clinical vaccine trial fraud. . 3. Scope of authorization Section 564(c) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3(c) ) is amended— (1) in paragraph (4), by striking and ; (2) by redesignating paragraph (5) as paragraph (6); and (3) by inserting after paragraph (4) the following: (5) the authorization is based on a certification by a medical research company or sponsor that no fraudulent material statements were made, and no material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under this subsection; and . 4. Revision and revocation Section 564(g)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3(g)(2) ) is amended— (1) in subparagraph (B), by striking or at the end; (2) by redesignating subparagraph (C) as subparagraph (D); and (3) by inserting after subparagraph (B) the following: (C) the Secretary determines that fraudulent material statements were made, or material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under subsection (c); or . 5. Exception to limitation on liability Section 2(b)(1) of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (21 U.S.C. 360bbb–0a note) is amended— (1) in subparagraph (A), by inserting , unless a fraudulent material statement was made, or material information was concealed, with respect to data collected from a clinical trial of the investigational drug before the semicolon; and (2) in subparagraph (B), by inserting , including a fraudulent material statement made, or material information concealed, with respect to data collected from a clinical trial of the investigational drug before the period. 6. Exception to targeted liability protections for pandemic and epidemic products Section 319F–3 of the Public Health Service Act ( 42 U.S.C. 247d–6d ) is amended— (1) in subsection (c)— (A) in paragraph (1)(A)— (i) by redesignating clauses (i), (ii), and (iii) as subclauses (I), (II), and (III), respectively; (ii) by moving subclauses (I), (II), and (III), as redesignated, 2 ems to the right; (iii) by striking the period at the end of subclause (III) and inserting ; and , as redesignated; (iv) by striking subsection (d), denote and inserting the following: subsection (d)— (i) denote ; and (v) by adding at the end the following: (ii) includes— (I) making a fraudulent material statement with respect to data collected from a clinical trial; or (II) concealing material information with respect to data collected from a clinical trial. ; and (B) in paragraph (5)(A)— (i) in the matter preceding clause (i), by striking subsection (d) if— and inserting subsection (d)— ; (ii) in clause (i)— (I) by inserting if before neither ; and (II) by striking or at the end; (iii) in clause (ii)— (I) by inserting if before such an enforcement ; and (II) by striking the period at the end and inserting ; and ; and (iv) by adding at the end the following: (iii) unless the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a covered person with respect to data collected from a clinical trial of a covered countermeasure. ; and (2) in subsection (e)— (A) by striking paragraph (7); and (B) by adding at the end the following: (11) Award of damages Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff may not be reduced because of any other award for damages the plaintiff may receive as a result of such claim. . 7. National Vaccine Injury Compensation Program Section 2122 of the Public Health Service Act ( 42 U.S.C. 300aa–22 ) is amended by adding at the end the following: (f) Liability (1) Fraudulent material statement No civil action against a vaccine manufacturer or vaccine sponsor shall be barred under this part if the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a vaccine manufacturer with respect to data collected from a clinical trial of a vaccine. (2) Award of damages (A) In general Notwithstanding any other provision of law, an plaintiff bringing a claim pursuant to paragraph (1) may— (i) seek compensation under the program established under this part; and (ii) concurrently bring an action with respect to such claim in any appropriate United States district court. (B) Award of damages Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff for a claim pursuant to paragraph (1) may not be reduced on the basis of any other damages the plaintiff may receive as a result of such claim. (3) Applicability with respect to COVID–19 vaccine Notwithstanding any other provision of law, a civil action against a vaccine manufacturer pursuant to paragraph (1) with respect to a vaccine related to COVID–19 may be made at any time. (4) COVID–19 definition In this section, the term COVID–19 means the coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 or the SARS–CoV–2. This term also relates to any and all variations of that virus of which there is no termination date for this term. 8. Liability hearing (a) Fraudulent material or statements In the case that the Secretary of Health and Human Services determines that a vaccine manufacturer or vaccine sponsor has made fraudulent material or statements or concealed material information with respect to a situation described in this Act, or an amendment made by this Act, the Secretary shall and provide such manufacturer or sponsor 30 days to refute a determination made in a hearing described in subsection (b). (b) Hearing (1) In general The Secretary shall determine a date, time, and format for a hearing under this subsection, including a requirement that the vaccine manufacturer or vaccine sponsor provide any requested document to the Secretary not more than five days before the hearing. (2) Format The format of a hearing under paragraph (1) shall be determined by the Secretary. (3) Publication Any written or verbal testimony submitted by the vaccine manufacturer or vaccine sponsor at the hearing under paragraph (1) shall be published on the internet website of the Secretary of Health and Human Services. (c) Does not provide information In the case that the vaccine manufacturer or vaccine sponsor does not respond to the Secretary in accordance with this section, an initial determination of fraud shall be maintained and shall have the full force and effect of this Act.